Under the collaboration, Array will develop assays and screen its proprietary lead generation library of 300,000 small molecules to identify both active site and allosteric modulators of certain Global Blood targets.
Array’s library will allow for rapid hit confirmation and subsequent lead optimization.
Array BioPharma president and chief scientific officer Kevin Koch said with the new collaboration the firm will look forward to deploy its drug discovery platform and share its expertise with companies like Global Blood, a venture-backed company founded by Third Rock Ventures.
"Our mutual goal is to accelerate the drug discovery and development process by combining Global Blood’s expertise in disease biology and computationally supported medicinal chemistry with Array’s established drug discovery platform," Koch added.